Grikkland - gríska - Εθνικός Οργανισμός Φαρμάκων

fresenius kabi hellas ae Λεωφ. Κηφισίας 64Α, 151 25 Μαρούσι Αττικής 6542909 - alanine; arginine; glycine; histidine; isoleucine; leucine; lysine acetate; methionine; phenylalanine; proline; serine; taurine; threonine; tryptophan, l-; tyrosine; valine; calcium chloride dihydrate; sodium glycerophosphate; magnesium sulfate; potassium chloride; sodium acetate trihydrate; zinc sulfate heptahydrate; dextrose(glucose) monohydrate; soya oil; triglycerides medium chain; olive oil, refined; fish oil (omega-3 polyunsaturated fatty acids) - inj.em.inf (ΓΑΛΑΚΤΩΜΑ ΓΙΑ ΕΓΧΥΣΗ) - alanine 14g; arginine 12g; glycine 11g; histidine 3g; isoleucine 5g; leucine 7,4g; lysine acetate 9,3g; methionine 4,3g; phenylalanine 5,1g; proline 11,2g; serine 6,5g; taurine 1g; threonine 4,4g; tryptophan, l- 2g; tyrosine 0,4g; valine 6,2g; calcium chloride dihydrate 0,74g; sodium glycerophosphate 4,18g; magnesium sulfate 1,2g; potassium chloride 4,48g; sodium acetate trihydrate 5,62g; zinc sulfate heptahydrate 0,023g; dextrose(glucose) monohydrate 209g; soya oil 60g; triglycerides medium chain 60g; olive oil, refined 50g; fish oil (omega-3 polyunsaturated fatty acids) 30g - combinations

Evrópusambandið - gríska - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - Καρκίνωμα, μη μικροκυτταρικός πνεύμονας - Αντινεοπλασματικοί παράγοντες - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Grikkland - gríska - Εθνικός Οργανισμός Φαρμάκων

laboratoires bailleul s.a., luxembourg 10-12 avenue pasteur,, l-2310 - - isotretinoin - soft.caps (ΚΑΨΑΚΙΟ, ΜaΛΑΚΟ) - 40mg/cap - isotretinoin 40mg - isotretinoin

Grikkland - gríska - Εθνικός Οργανισμός Φαρμάκων

laboratoires bailleul s.a., luxembourg 10-12 avenue pasteur,, l-2310 - - isotretinoin - soft.caps (ΚΑΨΑΚΙΟ, ΜaΛΑΚΟ) - 20mg/cap - isotretinoin 20mg - isotretinoin

Evrópusambandið - gríska - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - πεμετρεξίδη ημιπενταϋδρική δινάτριο - carcinoma, non-small-cell lung; mesothelioma - Αντινεοπλασματικοί παράγοντες - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra ενδείκνυται ως μονοθεραπεία για τη θεραπεία συντήρησης της τοπικά προχωρημένο ή μεταστατικό μη-μικροκυτταρικό καρκίνο του πνεύμονα εκτός από το κυρίως εκ πλακώδους ιστολογίας σε ασθενείς των οποίων η νόσος δεν έχει προχωρήσει αμέσως μετά από χημειοθεραπεία με βάση την πλατίνα. ciambra ενδείκνυται ως μονοθεραπεία για τη θεραπεία δεύτερης γραμμής, ασθενών με τοπικά προχωρημένο ή μεταστατικό μη-μικροκυτταρικό καρκίνο του πνεύμονα εκτός από το κυρίως εκ πλακώδους ιστολογίας.

Evrópusambandið - gríska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - Αντινεοπλασματικοί παράγοντες - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 και 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Evrópusambandið - gríska - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - Αντινεοπλασματικοί παράγοντες - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Evrópusambandið - gríska - EMA (European Medicines Agency)

krka, d.d., novo mesto - δεσλοραταδίνη - rhinitis, allergic, perennial; rhinitis, allergic, seasonal; urticaria - Αντιισταμινικά για συστηματική χρήση, - dasselta ενδείκνυται για την ανακούφιση των συμπτωμάτων που σχετίζονται με:αλλεργική ρινίτιδα, κνίδωση.

Evrópusambandið - gríska - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - Αιμοσφαιρινουρία, παροξυσμική - Επιλεκτικά ανοσοκατασταλτικά - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Grikkland - gríska - Εθνικός Οργανισμός Φαρμάκων

b. braun melsungen a.g, germany - ΔΕΞΤΡΌΖΗ(ΓΛΥΚΌΖΗΣ) ΜΟΝΟΫΔΡΙΚΌ, ΝΆΤΡΙΟ ΜΟΝΟΒΑΣΙΚΌ ΦΩΣΦΟΡΙΚΌ ΝΆΤΡΙΟ, dihydrate ΟΞΙΚΟΎ ΆΛΑΤΟΣ ΨΕΥΔΆΡΓΥΡΟΥ, ΜΈΣΗΣ ΑΛΥΣΊΔΑΣ ΜΕΡΙΚΉ ΓΛΥΚΕΡΊΔΙΑ (imwitor 742), ΈΛΑΙΟ ΣΌΓΙΑΣ, ΩΜΈΓΑ-3-ΟΞΎ, ΤΡΙΓΛΥΚΕΡΊΔΙΑ, ΙΣΟΛΕΥΚΊΝΗ, ΛΕΥΚΊΝΗ, ΛΥΣΊΝΗ ΥΔΡΟΧΛΩΡΙΚΉ, ΜΕΘΕΙΟΝΊΝΗ, ΦΑΙΝΥΛΑΛΑΝΊΝΗ, ΘΡΕΟΝΊΝΗ, ΤΡΥΠΤΟΦΆΝΗ, l-, ΒΑΛΊΝΗ, ΑΡΓΙΝΊΝΗ, ΙΣΤΙΔΊΝΗ ΥΔΡΟΧΛΩΡΙΚΉ, ΑΛΑΝΊΝΗ, ΓΛΥΚΊΝΗ, ΑΣΠΑΡΤΙΚΌ ΟΞΎ, ΤΟ ΓΛΟΥΤΑΜΙΝΙΚΌ ΟΞΎ, ΠΡΟΛΊΝΗ, ΣΕΡΊΝΗ, ΥΔΡΟΞΕΊΔΙΟ ΤΟΥ ΝΑΤΡΊΟΥ, ΧΛΩΡΙΟΎΧΟ ΝΆΤΡΙΟ, ΤΡΙΥΔΡΙΚΌ ΟΞΙΚΌ ΝΆΤΡΙΟ, ΟΞΙΚΌ ΚΆΛΙΟ, tetrahydrate ΟΞΙΚΟΎ ΆΛΑΤΟΣ ΜΑΓΝΉΣΙ - ΓΑΛΑΚΤΩΜΑ ΓΙΑ ΕΓΧΥΣΗ - 3,8%+12%+4% - 0005996101 - dextrose(glucose) monohydrate - 132.000000 g; 0013472350 - monobasic sodium phosphate dihydrate - 1.872000 g; 0005970456 - zinc acetate dihydrate - 5.264000 mg; ineof00797 - medium chain partial glycerides (imwitor 742) - 20.000000 g; 0008001227 - soya oil - 16.000000 g; ineof1925 - omega-3-acid triglycerides - 4.000000 g; 0000073325 - isoleucine - 2.256000 g; 0000061905 - leucine - 3.008000 g; 0000657272 - lysine hydrochloride - 2.728000 g; 0000059518 - methionine - 1.880000 g; 0000063912 - phenylalanine - 3.368000 g; 0000072195 - threonine - 1.744000 g; 0000073223 - tryptophan, l- - 0.544000 g; 0000072184 - valine - 2.496000 g; 0000074793 - arginine - 2.592000 g; 0000645352 - histidine hydrochloride - 1.624000 g; 0000056417 - alanine - 4.656000 g; 0000056406 - glycine - 1.584000 g; 0006899032 - aspartic acid - 1.440000 g; 0006899054 - glutamic acid - 3.368000 g; 0000147853 - proline - 3.264000 g; 0000056451 - serine - 2.880000 g; 0001310732 - sodium hydroxide - 0.781000 g; 0007647145 - sodium c - combinations